66th ASH Annual Meeting: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Oral and Poster Abstracts
Oral

Research, Clinical trials, Fundamental Science, Adult, Translational Research, Bispecific Antibody Therapy, Plasma Cell Disorders, Genomics, Bioinformatics, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Immunology, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Computational biology, Biological Processes, Technology and Procedures, Molecular biology, Profiling, Human, Study Population, Measurable Residual Disease , Omics technologies

San Diego Ballroom AB (Marriott Marquis San Diego Marina)

Moderators:

Leo Rasche, MD, Department of Internal Medicine II, University Hospital Wurzburg and Mark Bustoros, MD, Weill Cornell Medicine/New York Presbyterian Hospital

Disclosures:

Rasche: Amgen: Honoraria; BMS: Honoraria; GSK: Honoraria; Janssen: Honoraria; Skyline Dx: Research Funding; Pfizer: Honoraria. Bustoros: Menarini: Consultancy; Karyopharm: Consultancy; Epizyme: Consultancy; Takeda: Consultancy; BMS: Consultancy; Janssen: Consultancy.

2:00 PM

247

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Francesco Maura, MD¹, Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP², Holly Lee³^*, Kylee H Maclachlan, PhD, BSc, FRACP, FRCPA⁴, Michael Durante, MD, PhD⁵^*, Bachisio Ziccheddu¹^*, Meghan Menges²^*, Benjamin Diamond, M.D.¹^*, Marios Papadimitriou¹^*, Ariosto Siqueira Silva, PhD²^*, Praneeth Reddy Sudalagunta, PhD²^*, Noemie Leblay, PhD³^*, Sungwoo Ahn, PhD⁶^*, Ethan Fuller⁷^*, Edward Briercheck⁷^*, Phaedra Agius²^*, Doris K. Hansen, MD², Xiaofei Song, PhD⁸^*, Xiaohong Zhao, MD, PhD²^*, Mark B. Meads, PhD²^*, Jamie Teer²^*, Ross S Firestone, MD, PhD⁴, Juan-Jose Garces, PhD⁴^*, Tomas Jelinek⁹, Rachid Baz, MD², Melissa Alsina, MD²^*, Anusuyam Ramasubramanian⁷^*, Eric Smith, MD, PhD⁷, Sergio Giralt, MD⁴, Sham Mailankody, MD, MBBS¹⁰, Paola Neri, MD, PhD³, Saad Z. Usmani, MD¹¹, Frederick Locke, MD¹², Nizar J. Bahlis, MD³, Ola Landgren¹ and Kenneth H. Shain, MD, PhD²

¹University of Miami, Miami
²Moffitt Cancer Center, Tampa, FL
³Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
⁴Memorial Sloan Kettering Cancer Center, New York
⁵Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
⁶Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
⁷Dana Farber Cancer Institute, Boston
⁸Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁹Department of Hematooncology, University Hospital Ostrava, Ostrava, Ostrava-Mesto, Czech Republic
¹⁰Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
¹¹Memorial Sloan Kettering Cancer Center, New York, NY
¹²Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

2:15 PM

248

Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease

Kylee H Maclachlan, PhD, BSc, FRACP, FRCPA¹, Juan-Jose Garces, PhD²^*, Tala Shekarkhand, MS³^*, Sridevi Rajeeve, MD¹^*, Hamza Sloan Hashmi, MD³^*, Hani Hassoun, MD³, Malin Hultcrantz, MD³, Neha Korde, MD³, Carlyn Rose Tan, MD¹, Sham Mailankody, MD, MBBS³, Anish Simhal, PhD⁴^*, David J. Chung, MD, PhD⁵, Gunjan L. Shah, MD⁶, Michael Scordo, MD⁷, Sergio Giralt, MD⁸, Alexandra Maria Poos, PhD⁹^*, Lukas John, MD¹⁰^*, Yanming Zhang, MD¹¹, Robert Cimera, MS¹²^*, Maria E. Arcila, M.D.¹³^*, Juan E Arango Ossa¹⁴^*, Umesh Bhanot, MD¹⁵^*, Mala Jain, MD¹⁶^*, Tala Merghoub, MD¹⁷^*, Heather J. Landau, MD⁶, Alexander M. Lesokhin, MD¹, Saad Z. Usmani, MD³, Niels Weinhold, PhD¹⁸^*, Francesco Maura, MD¹⁹ and Urvi A. Shah, MD³

¹Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Memorial Sloan Kettering Cancer Center, New York
³Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Medical Physics Department, Memorial Sloan Kettering Cancer Center, New York
⁵Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY
⁸Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, NY
⁹Heidelberg Myeloma Center, Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
¹⁰Heidelberg Myeloma Center, Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
¹¹Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
¹²Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY
¹³Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁴Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁵Pathology Department, Memorial Sloan Kettering Cancer Center, New York
¹⁶Department of Pathology, Weill Cornell Medical Center, New York
¹⁷Memorial Sloan Kettering Cancer Center, New York, NY
¹⁸Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
¹⁹University of Miami, Coral Gables, FL

2:30 PM

249

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Marcella Kaddoura, MD¹, J Erin Wiedmeier-Nutor, MD, MPH², Vikas A. Gupta, MD PhD³, Bachisio Ziccheddu⁴^*, Suganti Shivaram, M.B.B.S⁵^*, Hongwei Tang, PhD⁶^*, Rodrigo Fonseca, MD⁷^*, Michael Durante, MD, PhD⁸^*, Shannon M Matulis, PhD⁹^*, Tomas Jelinek, MD, PhD¹⁰^*, Ola Landgren¹¹, Constantine S Mitsiades, MD¹², P. Leif Bergsagel, MD¹³, Esteban Braggio, PhD¹⁴, Lawrence H. Boise, PhD¹⁵, Rafael Fonseca, MD¹⁶, Shaji Kumar, MD¹⁷, Francesco Maura, MD¹⁸ and Linda B. Baughn, PhD⁵

¹Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
²Division of Hematology, Mayo Clinic, Phoenix, AZ
³Winship Cancer Institute of Emory University, Atlanta, GA
⁴Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami
⁵Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
⁷Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ
⁸University of Miami Miller School of Medicine, Miami, FL
⁹Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA
¹⁰Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
¹¹Sylvester Comprehensive Cancer Center, Miami, FL
¹²Dana-Farber Cancer Institute, Boston, MA
¹³Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ
¹⁴Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
¹⁵Emory University, Atlanta, GA
¹⁶Division of Hematology, Mayo Clinic, Paradise Valley, AZ
¹⁷Division of Hematology, Mayo Clinic, Rochester, MN
¹⁸University of Miami, Coral Gables, FL

2:45 PM

250

Increased Expression of the Sialyltransferase Gene ST3GAL1 Predicts Lack of Sustained MRD Negativity and Increased Risk of Progression in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients in the Maintenance/Observation Phase of Cassiopeia Study

Michael O'Dwyer, MD¹, Aideen Edele Ryan, BSc, PhD¹^*, Aoise O'Neill¹^*, Catherine Guerin-Charbonnel^2,3^*, Soraya Wuilleme, PhD⁴^*, Jill Corre, PharmD, PhD⁵^*, Herve Avet Loiseau, MD, PhD⁵, Li Peng, PhD⁶^*, Philippe Moreau, MD, PhD⁷^* and Stephane Minvielle, PhD^2,7^*

¹School of Medicine, University of Galway, Galway, Ireland
²Centre de Recherche en Cancérologie et Immunologie, 5INSERM, CNRS, Université d'Angers, Nantes, France
³Institut de Cancérologie de l’Ouest, Nantes, France
⁴Hematology Biology, University Hospital Hotel Dieu, Nantes, France
⁵Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
⁶Palleon Pharmaceuticals, Waltham, MA
⁷Department of Hematology, Nantes University Hospital, Nantes, France

3:00 PM

251

DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease

Benjamin G. Barwick, PhD¹, Robert M Chavez²^*, Doris R. Powell³^*, Yu Zhang, MS⁴^*, Mark Hamilton, MD⁵, Daniel Auclair, PhD⁶, George Mulligan, PhD⁵, Karen N Conneely, PhD⁷^*, Jonathan J Keats, PhD⁸, Paula M Vertino, PhD, BS⁹^*, Lawrence H. Boise, PhD² and Sagar Lonial, MD¹⁰^*

¹Hematology/Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
²Emory University, Atlanta, GA
³Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, GA
⁴Winship Cancer Institute / Hematology and Medical Oncology, Emory University, Atlanta, GA
⁵Multiple Myeloma Research Foundation, Norwalk, CT
⁶AstraZeneca, Waltham, MA
⁷Department of Human Genetics, Emory University School of Medicine, Atlanta, GA
⁸TGen, Phoenix, AZ
⁹University of Rochester, Rochester, NY
¹⁰Winship Cancer Institute of Emory University, Atlanta, GA

3:15 PM

252

Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma

Palak Bajaj¹^*, Ola Landgren², Damian J. Green, MD³ and David G. Coffey, MD⁴

¹Cancer Biology, Miller School of Medicine, University of Miami, Miami, FL
²Sylvester Comprehensive Cancer Center, Miami, FL
³Division of Transplantation and Cellular Therapy, University of Miami, Miami, FL
⁴Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651.O2.6 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes